InterMune (ITMN) Reports Smaller-Than-Expected Loss; Guides In-line
More News related to ITMN
- Morning Movers 11/17: ZOOM, SMTL, AGO, ABCW, XJT Higher; INOC, QUIK, PSUN, ERI, FTK, TBUS Lower
- InterMune (ITMN) Modifies On-Going Phase 2b Study of ITMN-191
- InterMune Announces Modification to On-Going Phase 2b Study of ITMN-191 in Patients with Chronic HCV Infection
- InterMune (ITMN) Reports Smaller-Than-Expected Loss; Guides In-line
- InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
InterMune Inc (NASDAQ: ITMN) reports a Q3 loss of $0.19, 2 cents better than the analyst estimate of ($0.21). Revenue for the quarter was $23.3 million, which compares to the estimate of $26.70 million.
Revenue: 2009 revenue, including Actimmune® and milestone payments from Roche, is expected to be in a range of approximately $45 to $50 million. Actimmune revenue represents approximately 50 percent of this revenue range. (Consensus is $48.02 million)
Related Categories
EarningsGuidance
Stocks Mentioned
-0.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
